Vanda Pharmaceuticals (VNDA) Long-Term Investments (2011 - 2019)
Vanda Pharmaceuticals' (VNDA) quarterly Long-Term Investments came in at $61.8 million in Q3 2019, up 393.94% quarter-over-quarter from $12.5 million in Q2 2019.
Vanda Pharmaceuticals (VNDA) Long-Term Investments (2011 - 2019) Analysis & Trends
Vanda Pharmaceuticals has disclosed Long-Term Investments across 2 years of filings, most recently posting $61.8 million for Q3 2019.
- Long-Term Investments for Q3 2019 came in at $61.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $61.8 million (changed N/A YoY), and the FY2011 annual result was $19.0 million, changed N/A from the prior year.
- Long-Term Investments came in at $61.8 million for Q3 2019 at Vanda Pharmaceuticals, up from $12.5 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $61.8 million in Q3 2019 to a low of $12.5 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 345.46 Mn | 143.15 Mn | 48.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 61.83 Mn |
| Jun 30, 2019 | 12.52 Mn |
| Dec 31, 2011 | 19.01 Mn |
| Sep 30, 2011 | 19.01 Mn |